Publications by authors named "David Giesbrecht"

Article Synopsis
  • Plasmodium vivax is increasingly problematic in tropical regions, particularly where Plasmodium falciparum is declining, due to its ability to cause relapse infections that hinder treatment efforts.
  • Researchers developed four specialized molecular inversion probe (MIP) genotyping panels targeting key genetic variations in P. vivax, aiming to better understand its population structure and resistance mechanisms.
  • Analysis using these panels on 866 infections in the Peruvian Amazon revealed significant findings, including transmission networks, gene mutations related to drug resistance, and potential vaccine targets, suggesting these tools can enhance research and control of P. vivax globally.
View Article and Find Full Text PDF

Most malaria rapid diagnostic tests (RDTs) detect histidine-rich protein 2 (PfHRP2) and PfHRP3, but deletions of and genes make parasites undetectable by RDTs. We analyzed 19,313 public whole-genome-sequenced field samples to understand these deletions better. deletion only occurred by chromosomal breakage with subsequent telomere healing.

View Article and Find Full Text PDF
Article Synopsis
  • In 2014, a significant mutation linked to artemisinin resistance, known as K13 561H, was first detected in Rwanda, making it crucial to monitor its spread.
  • Researchers utilized advanced blood preservation and pooled sequencing methods to assess the frequency of this mutation across multiple sites in Rwanda and neighboring countries from May 2022 to March 2023.
  • Results showed that K13 561H and 675V mutations were prevalent in Rwanda, with concerning additional mutations emerging, signaling threats to malaria treatment efficacy and control efforts in the region.
View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the prevalence of the Arg561His mutation in the Plasmodium falciparum k13 gene and other antimalarial resistance markers in Tanzania, particularly near the border with Rwanda, due to rising concerns about resistance in the region.* -
  • A total of 6855 blood samples from malaria-positive individuals were collected and genotyped, revealing an overall mutation prevalence of 7.7% in the Kagera region, with higher rates closer to Rwanda.* -
  • Genetic analysis indicates a possible connection between some local P. falciparum strains and those previously recorded in Rwanda, suggesting a regional spread of resistance.*
View Article and Find Full Text PDF

Novel antimalarials are urgently needed to combat rising resistance to available drugs. The imidazolopiperazine ganaplacide is a promising drug candidate, but decreased susceptibility of laboratory strains has been linked to polymorphisms in the cyclic amine resistance locus (PfCARL), acetyl-CoA transporter (PfACT), and UDP-galactose transporter (PfUGT). To characterize parasites causing disease in Africa, we assessed drug susceptibilities to ganaplacide in 750 .

View Article and Find Full Text PDF
Article Synopsis
  • Transmission of malaria is on the rise in tropical regions and poses challenges for treatment, leading to relapse infections.
  • Researchers developed four specialized molecular inversion probe (MIP) genotyping panels to analyze genetic variations related to antimalarial resistance and vaccines, focusing on specific SNPs.
  • The study analyzed 866 malaria infections in the Peruvian Amazon, identifying key transmission networks and genetic features that could enhance malaria control efforts in other affected areas.
View Article and Find Full Text PDF

Background: The Zanzibar archipelago of Tanzania has become a low-transmission area for . Despite being considered an area of pre-elimination for years, achieving elimination has been difficult, likely due to a combination of imported infections from mainland Tanzania and continued local transmission.

Methods: To shed light on these sources of transmission, we applied highly multiplexed genotyping utilizing molecular inversion probes to characterize the genetic relatedness of 282 isolates collected across Zanzibar and in Bagamoyo district on the coastal mainland from 2016 to 2018.

View Article and Find Full Text PDF

Background: Emerging artemisinin partial resistance and diagnostic resistance are a threat to malaria control in Africa. Plasmodium falciparum kelch13 (k13) propeller-domain mutations that confer artemisinin partial resistance have emerged in Africa. k13-561H was initially described at a frequency of 7.

View Article and Find Full Text PDF
Article Synopsis
  • The first detection of the K13 artemisinin resistance mutation 561H occurred in Rwanda, highlighting the need for ongoing surveillance in East Africa as new mutations emerge.
  • A study involved collecting malaria-positive samples from 39 health facilities across Rwanda, Uganda, Tanzania, and the DRC, revealing high frequencies of mutations 561H and 675V in Rwanda, indicating significant resistance levels.
  • The presence of candidate mutations, alongside other known resistance markers, suggests a concerning trend of increasing drug resistance in the region, potentially threatening malaria treatment effectiveness.
View Article and Find Full Text PDF
Article Synopsis
  • - In 2021 and 2023, the World Health Organization approved two malaria vaccines for children in African countries, raising concerns about genetic diversity in the malaria-causing parasite, Plasmodium falciparum, which could affect vaccine efficacy.
  • - The study analyzed 589 whole genome sequences from areas with varying malaria transmission rates in Mainland Tanzania, focusing on the Pfcsp gene's diversity and population structure to establish data before vaccine rollout.
  • - Findings indicated high polyclonality of the parasite in transmission areas, no significant population structure in the Pfcsp gene, and notable nucleotide diversity, particularly in the C-terminal region, suggesting ongoing natural selection in some regions.
View Article and Find Full Text PDF

Plasmodium falciparum with the histidine rich protein 2 gene (pfhrp2) deleted from its genome can escape diagnosis by HRP2-based rapid diagnostic tests (HRP2-RDTs). The World Health Organization (WHO) recommends switching to a non-HRP2 RDT for P. falciparum clinical case diagnosis when pfhrp2 deletion prevalence causes ≥ 5% of RDTs to return false negative results.

View Article and Find Full Text PDF

Background: Recent studies point to the need to incorporate the detection of non-falciparum species into malaria surveillance activities in sub-Saharan Africa, where 95% of the world's malaria cases occur. Although malaria caused by infection with Plasmodium falciparum is typically more severe than malaria caused by the non-falciparum Plasmodium species P. malariae, P.

View Article and Find Full Text PDF

Background: In 2021 and 2023, the World Health Organization approved RTS, S/AS01 and R21/Matrix M malaria vaccines, respectively, for routine immunization of children in African countries with moderate to high transmission. These vaccines are made of circumsporozoite protein ( but polymorphisms in this gene raises concerns regarding strain-specific responses and the long-term efficacy of these vaccines. This study assessed the genetic diversity, population structure and signatures of selection among parasites from areas of different malaria transmission in mainland Tanzania, to generate baseline data before the introduction of the malaria vaccines in the country.

View Article and Find Full Text PDF

Recent studies point to the need to incorporate non-falciparum species detection into malaria surveillance activities in sub-Saharan Africa, where 95% of malaria cases occur. Although infection is typically more severe, diagnosis, treatment, and control for , spp., and may be more challenging.

View Article and Find Full Text PDF

Background: Emerging artemisinin resistance and diagnostic resistance are a threat to malaria control in Africa. kelch13 (K13) propeller-domain mutations that confer artemisinin partial resistance have emerged in Africa. K13-561H was initially described at a frequency of 7.

View Article and Find Full Text PDF

Background: Recent data indicate that non-Plasmodium falciparum species may be more prevalent than thought in sub-Saharan Africa. Although Plasmodium malariae, Plasmodium ovale spp., and Plasmodium vivax are less severe than P.

View Article and Find Full Text PDF

Background: Emergence of artemisinin partial resistance (ART-R) in is a growing threat to the efficacy of artemisinin combination therapies (ACT) and the efforts for malaria elimination. The emergence of Kelch13 (K13) R561H in Rwanda raised concern about the impact in neighboring Tanzania. In addition, regional concern over resistance affecting sulfadoxine-pyrimethamine (SP), which is used for chemoprevention strategies, is high.

View Article and Find Full Text PDF

Recent data indicate that non- species may be more prevalent than previously realized in sub-Saharan Africa, the region where 95% of the world's malaria cases occur. Although spp., and are generally less severe than , treatment and control are more challenging, and their geographic distributions are not well characterized.

View Article and Find Full Text PDF

Background: Partial resistance of to the artemisinin component of artemisinin-based combination therapies, the most important malaria drugs, emerged in Southeast Asia and now threatens East Africa. Partial resistance, which manifests as delayed clearance after therapy, is mediated principally by mutations in the kelch protein K13 (PfK13). Limited longitudinal data are available on the emergence and spread of artemisinin resistance in Africa.

View Article and Find Full Text PDF

Malaria, especially Plasmodium falciparum infection, remains an enormous problem, and its treatment and control are seriously challenged by drug resistance. New antimalarial drugs are needed. To characterize the Medicines for Malaria Venture pipeline of antimalarials under development, we assessed the drug susceptibilities to 19 compounds targeting or potentially impacted by mutations in P.

View Article and Find Full Text PDF
Article Synopsis
  • - The study investigates the early distribution of artemisinin resistance mutations, specifically R561H, in Rwanda, which was first identified in 2014 but had unclear geographic spread.
  • - Researchers analyzed dried blood spot samples from a national HIV study conducted between 2014-2015, identifying multiple malaria infections and sequencing a significant number of samples to track mutations.
  • - Findings reveal that R561H was not only present in the previously reported area of Masaka but also in higher-transmission regions in southeastern Rwanda, highlighting a broader spread of this mutation than previously understood.
View Article and Find Full Text PDF

The Zanzibar archipelago of Tanzania has become a low-transmission area for Despite being considered an area of pre-elimination for years, achieving elimination has been difficult, likely due to a combination of imported infections from mainland Tanzania, and continued local transmission. To shed light on these sources of transmission, we applied highly multiplexed genotyping utilizing molecular inversion probes to characterize the genetic relatedness of 282 isolates collected across Zanzibar and in Bagamoyo District on the coastal mainland from 2016-2018. Overall, parasite populations on the coastal mainland and Zanzibar archipelago remain highly related.

View Article and Find Full Text PDF

Background: Malaria control in Liberia depends upon universal coverage with pyrethroid-impregnated long-lasting insecticidal nets (LLINs). Despite regular mass distribution, LLIN coverage and usage is patchy. Pyrethroid resistance in malaria vectors may further reduce LLIN efficacy.

View Article and Find Full Text PDF

Artemisinin partial resistance may facilitate selection of Plasmodium falciparum resistant to combination therapy partner drugs. We evaluated 99 P. falciparum isolates collected in 2021 from northern Uganda, where resistance-associated PfK13 C469Y and A675V mutations have emerged, and eastern Uganda, where these mutations are uncommon.

View Article and Find Full Text PDF

Recent developments in molecular biology and genomics have revolutionized biology and medicine mainly in the developed world. The application of next generation sequencing (NGS) and CRISPR-Cas tools is now poised to support endemic countries in the detection, monitoring and control of endemic diseases and future epidemics, as well as with emerging and re-emerging pathogens. Most low and middle income countries (LMICs) with the highest burden of infectious diseases still largely lack the capacity to generate and perform bioinformatic analysis of genomic data.

View Article and Find Full Text PDF